아드레날린 작용제: 간접 작용제

Displacers resemble noradrenaline but lack a catechol moiety, allowing active transport into synaptic vesicles. Once inside, they replace stored noradrenaline, which is then released to act on postsynaptic adrenoceptors. This mechanism enhances sympathomimetic effects without directly binding to receptors. Amphetamine and tyramine exemplify this displacement strategy.

Cocaine blocks the transporter responsible for catecholamine reuptake, preventing noradrenaline and dopamine from being removed from the synaptic cleft. This potentiates sympathomimetic action by prolonging neurotransmitter availability at adrenoceptors. As a local anesthetic with reuptake-inhibiting properties, cocaine produces both peripheral and central nervous system effects.

MAO inhibitors like selegiline and COMT inhibitors like entacapone prevent the breakdown and excretion of circulating catecholamines. By blocking these metabolic pathways, these enzyme inhibitors increase catecholamine concentration and duration of action, indirectly potentiating sympathomimetic responses without directly activating adrenoceptors.

Both amphetamine and cocaine stimulate central nervous system effects, particularly dopamine and serotonin release, producing euphoria and reward sensations. Although they use different mechanisms—displacement versus reuptake inhibition—both drugs enhance monoamine availability in the brain, driving their addictive potential and abuse liability.

Displacer agonists like amphetamine and tyramine lack a catechol moiety present in noradrenaline and direct-acting agents. This structural difference enables their active transport into synaptic vesicles, improves oral bioavailability, and enhances central nervous system penetration. The absence of the catechol group is essential to their displacement mechanism.

Tyramine, a displacer agonist found in fermented foods, mimics sympathetic responses by releasing stored catecholamines. When individuals take MAO inhibitors, tyramine metabolism is blocked, causing excessive accumulation and potentiation of sympathomimetic effects. This interaction can produce dangerous hypertensive responses, making dietary tyramine restriction important during MAO inhibitor therapy.

Indirect-acting agonists enhance endogenous catecholamine effects through displacement, reuptake inhibition, or enzyme inhibition rather than directly binding to adrenoceptors. Direct-acting agents bind directly to adrenoceptors to produce their effects. Indirect agents potentiate existing neurotransmitter activity, while direct agents independently activate receptors.